Integrated bulk and single-cell RNA sequencing identifies an aneuploidy-based gene signature to predict sensitivity of lung adenocarcinoma to traditional chemotherapy drugs and patients’ prognosis
PeerJ · 2024
DOI: 10.7717/peerj.17545 ↗Kurz gefasst
Fachartikel in der Zeitschrift PeerJ, 2024. Verfasst von Xiaobin Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Tangdu Hospital, Air Force Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms, Aneuploidy, Single-Cell Analysis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Patients with lung adenocarcinoma (LUAD) often develop a poor prognosis. Currently, researches on prognostic and immunotherapeutic capacity of aneuploidy-related genes in LUAD are limited.
Methods
Genes related to aneuploidy were screened based on bulk RNA sequencing data from public databases using Spearman method. Next, univariate Cox and Lasso regression analyses were performed to establish an aneuploidy-related riskscore (ARS) model. Results derived from bioinformatics analysis were further validated using cellular experiments. In addition, typical LUAD cells were identified by subtype clustering, followed by SCENIC and intercellular communication analyses. Finally, ESTIMATE, ssGSEA and CIBERSORT algorithms were employed to analyze the potential relationship between ARS and tumor immune environment.
Results
A five-gene ARS signature was developed. These genes were abnormally high-expressed in LUAD cell lines, and in particular the high expression of CKS1B promoted the proliferative, migratory and invasive phenotypes of LUAD cell lines. Low ARS group had longer overall survival time, higher degrees of inflammatory infiltration, and could benefit more from receiving immunotherapy. Patients in low ASR group responded more actively to traditional chemotherapy drugs (Erlotinib and Roscovitine). The scRNA-seq analysis annotated 17 cell subpopulations into seven cell clusters. Core transcription factors (TFs) such as CREB3L1 and CEBPD were enriched in high ARS cell group, while TFs such as BCLAF1 and UQCRB were enriched in low ARS cell group. CellChat analysis revealed that high ARS cell groups communicated with immune cells via SPP1 (ITGA4-ITGB1) and MK (MDK-NCl) signaling pathways.
Conclusion
In this research, integrative analysis based on the ARS model provided a potential direction for improving the diagnosis and treatment of LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Tangdu Hospital, Air Force Military Medical University, Xi'an, China.
- Department of Thoracic Surgery, The 986 Military Medical Hospital of the Air Force, Xi'an, China.
- Thoracic Surgery, Weinan Central Hospital, Weinan, China.
- Thoracic Surgery, Shaanxi Chenggu County Hospital, Chenggu, China.
Zitieren
APA
Wang, X., Chen, J., Li, C., Liu, Y., Chen, S., Lv, F., Lan, K., He, W., Zhu, H., Xu, L., Ma, K., & Guo, H. (2024). Integrated bulk and single-cell RNA sequencing identifies an aneuploidy-based gene signature to predict sensitivity of lung adenocarcinoma to traditional chemotherapy drugs and patients’ prognosis. PeerJ. https://doi.org/10.7717/peerj.17545
Vancouver
Wang X, Chen J, Li C, Liu Y, Chen S, Lv F, et al. Integrated bulk and single-cell RNA sequencing identifies an aneuploidy-based gene signature to predict sensitivity of lung adenocarcinoma to traditional chemotherapy drugs and patients’ prognosis. PeerJ. 2024. doi:10.7717/peerj.17545
BibTeX
@article{Wang2024,
author = {Wang, Xiaobin and Chen, Jiakuan and Li, Chaofan and Liu, Yufei and Chen, Shiqun and Lv, Feng and Lan, Ke and He, Wei and Zhu, Hongsheng and Xu, Liang and Ma, Kaiyuan and Guo, Haihua},
title = {Integrated bulk and single-cell RNA sequencing identifies an aneuploidy-based gene signature to predict sensitivity of lung adenocarcinoma to traditional chemotherapy drugs and patients’ prognosis},
journal = {PeerJ},
year = {2024},
doi = {10.7717/peerj.17545}
}
EUVIMED